Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App





Illumina Introduces Its Most Powerful and Sustainable Sequencer Yet at Medlab Middle East 2023

By LabMedica International staff writers
Posted on 06 Feb 2023
Print article
Image: The NovaSeq X Plus system revolutionizes human whole-genome sequencing (Photo courtesy of Illumina)
Image: The NovaSeq X Plus system revolutionizes human whole-genome sequencing (Photo courtesy of Illumina)

Illumina Inc. (San Diego, CA, USA) is introducing the NovaSeq X Plus, its most powerful and most sustainable sequencer yet, at the 22nd edition of Medlab Middle East Congress which is taking place live, in-person from 6-9 February 2023.

The NovaSeq X Plus system is the most powerful and most sustainable sequencer from Illumina and enables laboratories to complete their most ambitious ultra-high-throughput projects. Labs can scale their studies with three flow cell types and up to 16 Tb output per run on the dual flow cell NovaSeq X Plus system or up to 8 Tb on the single flow cell NovaSeq X system. Ultra-high-density flow cells and ultra-high-resolution optics enable output of up to 26 billion single reads per flow cell. XLEAP-SBS chemistry delivers the highest level of data accuracy and performance, and the increased stability enables remarkable sustainability benefits. The DRAGEN Bio-IT Platform, available onboard or in the cloud, provides award-winning accuracy for rapid, easy-to-use, and efficient genomic data analysis.

At Medlab Middle East 2023, Illumina is also demonstrating the NextSeq 1000 and NextSeq 2000 sequencing platforms that are redesigned from the ground up. Their flexibility, affordability, and scalability help both new and experienced users achieve fast turnaround times and reduced operating costs. With the wide range of available flow cells, they support a variety of applications including single-cell gene expression, special transcriptomics, whole-exome sequencing, total RNA sequencing, shotgun metagenomics and infectious disease testing.

Additionally, Illumina is holding a half-day workshop on Genomics for Rare Diseases in the Middle East, featuring the latest findings related to the genomic basis of rare diseases and providing powerful insights into disease mechanisms and therapeutic approaches. As genomic sequencing becomes more available in the hospital setting, the expert panel discussion will be examining standardization, drivers & local challenges to implementation of genomic sequencing and how this is changing clinical practice. The program consists of scientific presentations from top experts in rare diseases, diagnostics and targeted testing followed by Q&A sessions. Guest speakers will be joining panel discussion with Illumina experts to identify the research, regulatory and access policy drivers to enable integration of whole genome sequencing into a healthcare setting.

Related Links:
Illumina Inc.

Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Epstein-Barr Virus Test
Mononucleosis Rapid Test
New
TRAb Immunoassay
Chorus TRAb

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.